Detalhe da pesquisa
1.
Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study.
Gastric Cancer
; 26(6): 1020-1029, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37610558
2.
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
Oncologist
; 27(8): e642-e649, 2022 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35579511
3.
Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer.
Support Care Cancer
; 30(6): 5351-5359, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35292848
4.
Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203).
Tohoku J Exp Med
; 254(1): 49-55, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34053967
5.
The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
BMC Cancer
; 19(1): 941, 2019 Oct 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31604467
6.
Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study.
Tohoku J Exp Med
; 245(1): 21-28, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29743448
7.
Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201.
J Gastrointest Oncol
; 14(2): 676-691, 2023 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37201044
8.
Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study.
Eur J Cancer
; 169: 166-178, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35569283
9.
Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial.
Anticancer Res
; 42(5): 2683-2687, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35489762
10.
Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial.
Anticancer Res
; 42(4): 2009-2015, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35347022
11.
Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer.
BMJ Open
; 12(5): e048833, 2022 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35534074
12.
Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.
Front Oncol
; 12: 939425, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36439491
13.
[A case of simultaneous bilateral metastatic ovarian tumor of colon cancer followed by FOLFOX4 Regimen and oral tegafur/uracil+oral leucovorin after R0 operation].
Gan To Kagaku Ryoho
; 36(9): 1583-6, 2009 Sep.
Artigo
em Japonês
| MEDLINE | ID: mdl-19755839
14.
[Reduction of oxaliplatin-related neurotoxicity by Gosha-jinki-gan].
Gan To Kagaku Ryoho
; 35(5): 863-5, 2008 May.
Artigo
em Japonês
| MEDLINE | ID: mdl-18487931
15.
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study).
Cancer Chemother Pharmacol
; 79(1): 29-36, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27878354
16.
A new two-stage esophagectomy followed by pancreaticoduodenectomy.
Am Surg
; 76(12): 1442-4, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21265372